The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Immortal time bias in a claims-database study

This is a generated summary. It shows the 5 most-liked posts from a topic of 35, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
MA
mi.almeidaTL2 Moderator14 Jul 2025#1

Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable.

I have seen FLOW (N Engl J Med, 2024) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

54 likes 12mo
FW
f.wojcikTL2 Moderator1 Aug 2025#11
l.trevino, post #9: Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had been repeating something I had not checked carefully enough. Go to post

Picking up post #8: that is the part I would want checked first.

Choosing the worst interpretation: "The confidence interval includes a harmful effect" is true if the CI goes from -1 to +5. But assuming the worst-case scenario is not how you use the evidence. The point estimate and the precision both matter.

27 likes in reply to #9 12mo
KK
k.karlsenTL2 Moderator21 Aug 2025#26
mi.almeida, post #1: Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows. My reading is that the trial is sound for its own… Go to post

This follows post #23 rather than contradicting it.

Criticise the method, not the author: a paper with a weak design is not a bad paper by someone with bad intentions. It is a paper that answers a limited question. Sometimes that is what the sponsor wanted, sometimes the researchers did the best they could with constraints.

28 likes in reply to #1 11mo
F
FFaulknerTL3Regular24 Aug 2025#29
e.okafor, post #10: Picking up post #7: that is the part I would want checked first. Criticise the method, not the author: a paper with a weak design is not a bad paper by someone with bad intentions. It is a paper that answers a limited question. Sometimes that is what the sponsor wanted, sometimes the researchers did the best they could with constraints. Go to post

Coming back to post #27, because the follow-up matters more than the original answer.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

22 likes in reply to #10 11mo
EA
e.adeyemiTL2 Moderator30 Aug 2025#34
m.dalgaard, post #31: Multiple comparisons: if a paper reports many outcomes, the chance of a spurious association by random chance is real. Pre-specification of primary outcomes matters and secondary analyses are weaker evidence. Go to post

I read post #32 twice before replying, because I had assumed the opposite.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

30 likes in reply to #31 11mo

Read the full topic (35 posts)

This topic was closed 45 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

TopicParticipantsRepliesViewsActivity
Critiquing an observational claim about a class effect
Posting this under the heading it deserves: Critiquing an observational claim about a class effect Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
VRRIJV 2 6.9k 14mo
A well-designed study with a badly written abstract
Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with LEADER ( N Engl J Med ,…
RCMICBMRPN+117 128 7.2k 14mo
Confounding by indication, explained with a concrete example
On the subject in the title: Confounding by indication, explained with a concrete example Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-2 ( N Engl J Med ,…
TVARBDSBCD+21 25 21k 11mo
A claim built entirely on a subgroup analysis
A claim built entirely on a subgroup analysis Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support of a claim I do…
ASKHMIASNP+71 80 1.1k 14mo
A structured critique template this community uses — a second dataset
On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
PRFLKBACAW+47 51 16k 15h

Related topics — sharing the tags risk of bias, observational data, disputed

TopicParticipantsRepliesViewsActivity
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with STEP 4 ( JAMA , 2021) and…
EDCRFKTVIA+11 15 4k 10mo
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset
Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med ,…
OLIADSRFDO+18 22 656 13h
Follow-up: A supplier that answers analytical questions with restated claims
A supplier that answers analytical questions with restated claims — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually better than…
CCPYESTCB+74 82 2.8k 6mo
Journal club: semaglutide in MASH, and surrogate endpoints
Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURMOUNT-2 (…
MDSRSGSLSC+24 28 17k 15h
When a preprint is the best available evidence and we say so
When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…
CPNMKMJE+148 160 31k 11mo